Holen Sie sich die Stockscreener-App
9.67
2.76%
0.26
Vorhandelsmarkt:
9.72
0.05
+0.52%
Schlusskurs vom Vortag:
$9.41
Offen:
$9.39
24-Stunden-Volumen:
3.71M
Relative Volume:
0.68
Marktkapitalisierung:
$2.43B
Einnahmen:
$874.84M
Nettoeinkommen (Verlust:
$263.86M
KGV:
8.0376
EPS:
1.2031
Netto-Cashflow:
$327.41M
1W Leistung:
+0.83%
1M Leistung:
+17.64%
6M Leistung:
+50.62%
1J Leistung:
+37.36%
1-Tages-Spanne:
$9.37
$9.68
1-Wochen-Bereich:
$9.34
$9.98
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.67 | 2.40B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - Stock Traders Daily
BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com
BCRX Should I Buy - Intellectia AI
BCRX.O Forecast — Price Prediction for 2026. Should I Buy BCRX.O? - Intellectia AI
BCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
BCRX.O PE Ratio & Valuation, Is BCRX.O Overvalued - Intellectia AI
Free cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets
BCRX PE Ratio & Valuation, Is BCRX Overvalued - Intellectia AI
BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
Aberdeen Group Boosts Stake in BioCryst Pharmaceuticals - National Today
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment - Sahm
R&D Leadership Shake-Up at BioCryst (BCRX) Could Be A Game Changer For Its Pipeline Strategy - Sahm
BioCryst (BCRX) Chief R&D Officer receives large stock option and RSU inducement grants - Stock Titan
Sandeep Menon of BIOCRYST PHARMACEUTICALS (BCRX) submits Form 3 - Stock Titan
RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating - Moomoo
New Strong Buy Stocks for June 25th - MSN
BioCryst (BCRX) soars 13% on acquisition buzz - MSN
BIOCRYST PHARMACEUTICALS INC (BCRX) Fundamental Analysis & Valuation - ChartMill
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%Here's What Happened - MarketBeat
BioCryst names Sandeep Menon as chief R&D officer By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals Appoints Dr. Sandeep M. Menon as Chief Research and Development Officer - Quiver Quantitative
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - The Manila Times
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Operating cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView — Track All Markets
BioCryst taps AMVUTTRA, PAXLOVID veteran to lead R&D effort - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) stock price, news, quote and history - Yahoo Finance Singapore
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Yahoo Finance
BCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioCryst Pharmaceuticals Inc (BO1.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Technical Reactions to BCRX Trends in Macro Strategies - Stock Traders Daily
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
12 new BioCryst hires receive stock awards tied to 157,300 shares - Stock Titan
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals Stock: Navigating Biotech Innovation and Investor Opportunities in Rare Dis - AD HOC NEWS
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co. - MarketBeat
Rate Cut: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio - Investing.com Canada
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):